37 results about "Schistosoma Japonicum Infection" patented technology

The invention discloses an anti-parasitical medicine in situ setting slow release injection and a preparation method thereof. The injection comprises the following components in ratio: 1-80g of an anti-parasitic disease medicine, 1-100g of a biodegradable high polymer material, 2-300mL of a dispersion medium and 0-50g of a solubilizer, wherein the content of the anti-parasitic disease medicine is1-800mg/mL. The injection can maintain long-term control effect when being medicated to a medicated object only once, the medicated object is protected from being infected by pathogens, propagation ofparasitic diseases can be economically and effectively controlled, material safety is high, prescription of a commercially available anti-parasitic disease medicine is simplified, compliance of the medicated object is improved, and control cost is reduced. Meanwhile, subcutaneous injection slow release injection is prepared by innovatively using a molluscicide, namely niclosamide, of the WHO, andthe effect of preventing schistosoma japonicum infection is achieved. The anti-parasitical medicine in situ setting slow release injection is simple in the preparation method, has good stability andis easy to use and popularize.

The invention discloses a urine biomarker for Japanese schistosomiasis early diagnosis. The urine biomarker is one or more of a xanthurenic acid, a naphthalenesulfonic acid, or enanthylcarnitine. Sensitivity and specificity of the marker are greater than 0.9, and an area under the curve (AUC) is greater than 0.9, indicating that the three indicators have better predictability and may be used for the Japanese schistosomiasis early diagnosis. The invention further discloses a metabolomics-based screening method for the urine biomarker for the Japanese schistosomiasis early diagnosis. By constructing a mouse Japanese schistosomiasis model, ultra performance liquid chromatography-tandem mass spectrometry is used to perform metabolomics analysis on mouse urine, and a characteristic differentialmetabolite, that is, the biomarker for the Japanese schistosomiasis early diagnosis, between a normal mouse and a Japanese schistosomiasis-infected mouse is found and analyzed. The screening method is non-invasive, convenient and fast, and can accurately reflect a metabolic spectrum difference between the Japanese schistosomiasis-infected mouse and the normal mouse and have high specificity.

The invention relates to a method for detecting insecticide resistance of schistosoma japonicum eggs to praziquantel in vitro, belonging to the technical field of antiparasitic drugs. The method comprises the following steps of: collecting 1,000-2,000 eggs from the feces of schistosoma japonicum infected hosts, respectively immigrating the 1,000-2,000 eggs in a flask of 50mL of normal saline containing praziquantel of 5*10-6mol/L and single control normal saline, and placing the eggs in the dark environment for 24h; then immigrating the eggs in fresh dechlorinated tap water, and hatching miracidia under irradiation of an incandescent bulb of 28 DEG C; after hatching starts, collecting tap water containing the miracidia for one time with a centrifuge tube of 50mL every 30 min; centrifuging after adding few drops of Lugol's iodine solution; collecting the miracidia, observing the miracidia under a microscope, counting, and calculating the hatching rate of eggs; setting normal saline control, and repeating for 3 times; detecting the insecticide resistance of the schistosoma japonicum eggs to praziquantel by observing the hatching rate of eggs. The method is fast, simple, convenient, sensitive and reliable and is suitable for fast detecting and monitoring the insecticide resistance of the schistosoma japonicum to praziquantel on site.

The invention relates to a hybridoma for secreting an anti-recombinant schistosoma japonica enolase specific monoclonal antibody as well as a preparation method and application of the hybridoma, and belongs to the technical fields of gene engineering, preparation of monoclonal antibodies and immunologic diagnosis. The hybridoma JYG-1 capable of secreting the anti-recombinant schistosoma japonica enolase (Sj Enolase protein) specific monoclonal antibody is preserved in the Common Microbiology Center of CCCCM (China Committee for Culture Collection of Microorganisms) and has the preservation number of CGMCC NO. 9910. The hybridoma JYG-1 can secrete the anti-recombinant schistosoma japonica enolase (Sj Enolase) specific monoclonal antibody JYGENmb-1. The monoclonal antibody JYGENmb-1 can be combined with Sj Enolase protein specificity of schistosoma japonica, a sandwich ELISA method for detecting Sj Enolase protein is provided, and the monoclonal antibody can be applied to establishing various immunological methods for detecting Sj Enolase protein in schistosoma japonica infected human and animal blood and excreting secretion.

The invention discloses a serum biomarker for early diagnosis of schistosomiasis japonica. The serum biomarker is phosphatidylcholine and/or palmitoyl choline. The sensitivity and specificity of the marker are both greater than 0.9, and the under-curve area (AUC) is greater than 0.9, which indicates that the two indexes have favorable predictability and can be used for early diagnosis of schistosomiasis japonicum katsurada. The invention further discloses a screening method of the serum biomarker for early diagnosis of schistosomiasis japonica based on metabonomics. A mouse schistosomiasis japonica model is constructed, and the metabonomics analysis is carried out on mouse serum by utilizing an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and characteristic differential metabolites between a normal mouse and a schistosomiasis japonica infected mouse are found and analyzed, namely, the schistosomiasis japonica early diagnosis biomarker is obtained. The screening method has the characteristics of convenience and quickness, can accurately reflect the metabolic spectrum difference between a schistosomiasis japonicum infected mouse and a normal mouse, and is high in specificity.

The invention discloses a recombinant expression carrier containing a schistosoma japonicum gene which is a schistosoma japonicum heat shock protein 60 gene. The invention also discloses a preparation method of the schistosoma japonicum heat shock protein 60 and the application of the recombinant expression carrier. The recombinant expression carrier containing the schistosoma japonicum gene can highly express the schistosoma japonicum heat shock protein 60 gene, and the highly expressed recombinant schistosoma japonicum Hsp60 protein can induce mouse to generate the protection function of resisting the infection of schistosoma japonicum at a certain level.

The invention provides a Japanese schistosomiasis vaccine combined immunizing method and an application of the Japanese schistosomiasis vaccine, and belongs to the field of schistosomiasis prevention and treatment. According to the immunizing scheme, recombinant adenovirus vaccine (rAdV-SjTPI.opt) of optimized schistosoma japonicum triosephosphate isomerase (SjTPI.opt) is subjected to primary immunizations in an intramuscular way, and is subjected to reinforced immunization by recombinant protein vaccine (rSjTPI) in a hypodermatic way, and the immunization interval is 2 weeks. The immunization scheme has the effect of preventing Japanese schistosomiasis infection, is capable of inducing a host to generate body fluid with high level and cell immunity response after an animal is immunized, and the protecting force can be 70 percent. Furthermore, in the scheme, the two vaccines are simple to prepare, the immunization operation is convenient, and the vaccines have an excellent application prospect.

The invention relates to a schistosome antigen for inducing short-lived antibody response and a schistosomiasis diagnostic kit and a detection method for detecting the antibody response, belonging to the technical field of schistosomiasis prevention and treatment and immunological diagnosis. Protein molecules such as glyceraldehyde-3-phosphate dehydrogenase (SjGAPDH) and the like capable of inducing short-lived antibody response in a schistosomiasis infected person through an immunoblotting technology and a mass spectrometry method are identified. A recombinant SjGAPD protein is prepared by adopting a genetic engineering technology, and an enzyme-linked immunosorbent assay detection kit and detection method for detecting anti-SjGAPDH protein specific short-lived antibody response in the schistosomiasis infected person by the recombinant SjGAPD protein are established to diagnose the schistosomiasis infected person and estimate the treatment effect.

The invention discloses a recombinant expression carrier containing a schistosoma japonicum gene which is a schistosoma japonicum thioredoxin peroxidase II gene. The invention also discloses a preparation method of the schistosoma japonicum thioredoxin peroxidase II and the application of the recombinant expression carrier. The recombinant expression carrier containing the schistosoma japonicum gene can highly express the schistosoma japonicum thioredoxin peroxidase II, and the highly expressed recombinant schistosoma japonicum thioredoxin peroxidase II can induce mouse to generate the protection function of resisting the infection of schistosoma japonicum at a certain level.

A double peptide-DNA vaccine based on T-cell epitope for preventing and treating the Japanese schistosome infection features that its eucaryotic expression carrier carrying the epitope peptide coding gene is wrapped by the protein containing the epitope peptide. The amino acid sequence of said T-cell epitope peptide is AKQYNICCKFKELLD. Said vaccine can be prepared by cationic peptide carrying technique.

The invention discloses a method for detecting schistosoma japonicum infection by using a host exosome miRNA-142a-3p. A nucleotide sequence of the serum exosome miR-142a-3p is as shown in SEQ ID NO 1,and the method for detecting the schistosoma japonicum infection is established based on primers with a nucleotide sequence as shown in SEQ ID NO 2. The method for detecting the schistosoma japonicuminfection by using the host exosome miRNA-142a-3p is rapid, sensitive, specific and stable to detect. According to the method, serum of patients is directly extracted so that the trauma of the patients is reduced, and the trauma is small; a q-PCR detection method is used, and the sensitivity is high; and the q-PCR detection method has high sensitivity. At present, a mature exosome extraction kitis provided, meanwhile, q-PCR detection is a commonly used technology in a laboratory and is relatively simple. Therefore, the method is worth popularizing and has a good clinical application value.

The invention relates to the use of schistosoma japonicum infection, and an application of components of schistosoma japonicum to the prevention and treatment of human tumors. The schistosoma japonicum components include but are not limited to eggs, miRNAs, exosomes, and proteins. The present invention shows for the first time that the schistosoma japonicum components have an effect of resisting avariety of host tumors including but not limited to liver cancer. The schistosoma japonicum and the components thereof come into play by inducing host-specific and non-specific immune responses, or modulating tumor-associated genes and signaling pathways, or directly killing tumor cells. The schistosoma japonicum and the components thereof have application value in the prevention and treatment ofhuman tumors.

A schistosomulum cell type vaccine for preventing schistosomiasis is prepared through collecting the schistosomulums from the rabit infected by Japanese schistosome for 14-24 days, fast cutting in aseptic mode, digestion by pancreatin, taking supernatant, adding Ca or Mg ion type D-Hankí»s liquid to terminate the digestion to obtain living cells, freezing them to obtain the dead cells and using said living cells or dead cells as vaccine.

A garlic seed immersion fluid for killing japaneses schistosomulum, is composed of garlic seed immersion fluid and water. The garlic seed is peeled off the skin, and then squeezed by clear water dechlorinated after airing to become the raw liquor of the garlic seed fluid, at last the garlic seed immersion fluids of various concentrations above 0.79% are prepared by distilled water for killing japaneses schistosomulum. A great variety of emulsion, slurry, aqua and oil are prepared by the garlic seed immersion fluid as protective agents for skin protection against the penetration of the japaneses schistosomulum, namely avoiding the infection of the japaneses schistosomulum. The garlic seed immersion fluid is natural product, the features of which comprise small skin irritation, low price, economy, practicality.